Company Description
Harrow Health, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development.The Pharmaceutical Compounding segment focuses on the operations of ImprimisRx business. The comp...
Harrow Health, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development.The Pharmaceutical Compounding segment focuses on the operations of ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
Valuation
Price to Sales Ratio
3.19
Price to Book Ratio
20.60
Price to Cash Flow Ratio
45.49
Enterprise Value to EBITDA
113.11
Enterprise Value to Sales
5.32
Efficiency
Total Asset Turnover
0.93
Liquidity
Current Ratio
6.24
Quick Ratio
5.81
Cash Ratio
5.21
Profitability
Gross Margin
74.87
Operating Margin
2.43
Pretax Margin
-24.80
Net Margin
-24.85
Return on Assets
-23.12
Return on Equity
-93.62
Return on Total Capital
2.53
Capital Structure
Total Debt to Total Assets
79.28
Officers and Executives
Name | Age | Officer Since | Title |
---|---|---|---|
Mr. Mark L. Baum | 48 | 2006 | Chairman & Chief Executive Officer |
Mr. Andrew R. Boll | 37 | 2011 | Chief Financial Officer & Secretary |
Dr. Larry M. Dillaha | 57 | - | Chief Medical Officer |
Mr. Andrew Livingston | - | - | Chief Innovation Officer |
Mr. John P. Saharek | 60 | 2012 | Vice President-Commercialization |
Insider Actions
01/02/2023 |
Mark L. Baum Chief Executive Officer; Director |
35,179 | Derivative/Non-derivative trans. at $14.76 per share. | 519,242 |
01/02/2023 |
Andrew R. Boll Chief Financial Officer |
9,602 | Derivative/Non-derivative trans. at $14.76 per share. | 141,725 |
01/02/2023 |
Mark L. Baum Chief Executive Officer; Director |
88,000 | Derivative/Non-derivative trans. at $0 per share. | 0 |
01/02/2023 |
Andrew R. Boll Chief Financial Officer |
23,000 | Derivative/Non-derivative trans. at $0 per share. | 0 |
12/22/2022 |
Mark L. Baum Chief Executive Officer; Director |
25,000 | Acquisition at $13.39 per share. | 334,750 |
12/22/2022 |
Andrew R. Boll Chief Financial Officer |
2,500 | Acquisition at $13.54 per share. | 33,850 |
12/22/2022 |
R. Lawrence van Horn Director |
1,860 | Acquisition at $13.42 per share. | 24,961 |
12/21/2022 |
Martin A. Makary Director |
25,000 | Acquisition at $13.37 per share. | 334,250 |
12/14/2022 |
Opaleye Management, Inc. |
16,183 | Acquisition at $10.52 per share. | 170,245 |
12/14/2022 |
Opaleye Management, Inc. |
415,000 | Acquisition at $10.52 per share. | 4,365,800 |
09/30/2022 |
Richard L. Lindstrom Director |
40,000 | Disposition at $12.62 per share. | 504,800 |
09/28/2022 |
Opaleye Management, Inc. |
1,085 | Acquisition at $9.77 per share. | 10,600 |
09/28/2022 |
Opaleye Management, Inc. |
10,000 | Acquisition at $9.77 per share. | 97,700 |
04/13/2022 |
Opaleye Management, Inc. |
2,832 | Acquisition at $6.76 per share. | 19,144 |
04/13/2022 |
Opaleye Management, Inc. |
10,000 | Acquisition at $6.76 per share. | 67,600 |
04/12/2022 |
Opaleye Management, Inc. |
3,557 | Acquisition at $6.75 per share. | 24,009 |
04/12/2022 |
Opaleye Management, Inc. |
25,000 | Acquisition at $6.75 per share. | 168,750 |
02/19/2022 |
Andrew R. Boll Chief Financial Officer |
20,605 | Derivative/Non-derivative trans. at $7.87 per share. | 162,161 |
02/19/2022 |
John P. Saharek President, ImprimisRx |
25,923 | Derivative/Non-derivative trans. at $7.87 per share. | 204,014 |
02/19/2022 |
Andrew R. Boll Chief Financial Officer |
50,000 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/19/2022 |
John P. Saharek President, ImprimisRx |
50,000 | Derivative/Non-derivative trans. at $0 per share. | 0 |
01/28/2022 |
Opaleye Management, Inc. |
1,343 | Acquisition at $6.89 per share. | 9,253 |
01/28/2022 |
Opaleye Management, Inc. |
5,000 | Acquisition at $6.89 per share. | 34,450 |
MarketWatch News on HROW
-
Imprimis Pharma initiated as buy at B Riley FBR
- Ciara Linnane
-
Express Scripts opts for $1 alternative to Turing’s $750 Daraprim
- Jonathan D. Rockoff
-
Valeant’s use of specialty pharmacy channel is typical of the industry
- Francine McKenna
-
Duckburg Economics: Pricing and Scarcity in Drugs
- Barron's Online
Other News on HROW
-
Harrow Health, Inc. (HROW) Q3 2022 Earnings Call Transcript
- Seeking Alpha
-
- Edgar Online - (EDG = 10Q, 10K)
-
Harrow Health gains as subsidiary launches topical antibiotic
- Seeking Alpha
-
SA Interview: Value Investing With Michigan Value Investor
- Seeking Alpha
-
SRK Capital H1 2022 Investor Letter
- Seeking Alpha
-
Private Capital Buys 4, Sells 1 in 2nd Quarter
- GuruFocus.com
-
- Edgar Online - (EDG = 10Q, 10K)
-
Harrow Health files for $300M mixed shelf offering
- Seeking Alpha
- Loading more headlines...